全文获取类型
收费全文 | 17517篇 |
免费 | 1281篇 |
国内免费 | 511篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 454篇 |
妇产科学 | 187篇 |
基础医学 | 1266篇 |
口腔科学 | 248篇 |
临床医学 | 1795篇 |
内科学 | 2817篇 |
皮肤病学 | 174篇 |
神经病学 | 749篇 |
特种医学 | 524篇 |
外国民族医学 | 1篇 |
外科学 | 1012篇 |
综合类 | 2023篇 |
预防医学 | 1669篇 |
眼科学 | 338篇 |
药学 | 4876篇 |
12篇 | |
中国医学 | 854篇 |
肿瘤学 | 262篇 |
出版年
2024年 | 30篇 |
2023年 | 347篇 |
2022年 | 555篇 |
2021年 | 783篇 |
2020年 | 655篇 |
2019年 | 699篇 |
2018年 | 696篇 |
2017年 | 594篇 |
2016年 | 541篇 |
2015年 | 490篇 |
2014年 | 1115篇 |
2013年 | 1221篇 |
2012年 | 1051篇 |
2011年 | 1189篇 |
2010年 | 866篇 |
2009年 | 747篇 |
2008年 | 800篇 |
2007年 | 814篇 |
2006年 | 594篇 |
2005年 | 588篇 |
2004年 | 544篇 |
2003年 | 444篇 |
2002年 | 348篇 |
2001年 | 281篇 |
2000年 | 291篇 |
1999年 | 260篇 |
1998年 | 201篇 |
1997年 | 221篇 |
1996年 | 169篇 |
1995年 | 194篇 |
1994年 | 174篇 |
1993年 | 140篇 |
1992年 | 148篇 |
1991年 | 143篇 |
1990年 | 151篇 |
1989年 | 103篇 |
1988年 | 117篇 |
1987年 | 82篇 |
1986年 | 89篇 |
1985年 | 123篇 |
1984年 | 108篇 |
1983年 | 65篇 |
1982年 | 89篇 |
1981年 | 74篇 |
1980年 | 69篇 |
1979年 | 77篇 |
1978年 | 40篇 |
1977年 | 64篇 |
1976年 | 36篇 |
1975年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
目的:评定LC-MS/MS法测定人血浆中布康唑浓度的不确定度。方法:分析测定过程中不确定度的来源,包括对照品的称量、仪器误差、标准溶液的配制、含药血浆样品的配制、血浆样品的处理、标准曲线的拟合、基质效应、重复性等,评定各来源分量的不确定度,计算合成不确定度和扩展不确定度。结果:人血浆中低(60.0 pg·mL-1)、中(600.0 pg·mL-1)、高(6 400.0 pg·mL-1)浓度布康唑的扩展不确定度分别为5.62,63.90,626.26 pg·mL-1(k=2,P=95%)。结论:LC-MS/MS法测定人血浆中布康唑浓度的不确定度主要由基质效应、血浆样品的处理(提取回收率),仪器误差、重复性(精密度)引入。 相似文献
13.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
14.
目的:建立液相色谱-串联质谱法(UPLC-MS/MS)同时测定人血浆中头孢哌酮与舒巴坦的浓度,分析头孢哌酮/舒巴坦血药浓度监测结果,为临床合理用药提供参考。方法:以氯唑沙宗为内标,采用Waters BEHC18柱(2.1 mm×100 mm,1.7 μm)进行分离,通过串联质谱仪,负离子检测模式下,以多反应监测(MRM)方式进行定量测定。对某院2018年以不同给药方案进行治疗的73例住院患者测定的头孢哌酮/舒巴坦血药浓度结果进行分析。结果:头孢哌酮与舒巴坦在测定条件下1~200 mg·L-1范围内线性关系良好,两者日内精密度RSD均<10%,基质效应分别为(72.77±0.99)%与(75.72±0.11)%,提取回收率均>90%。73例患者共监测血药浓度96次,其中不同给药方案2 g,q8 h(43例次);2 g,q12 h(26例次);2 g,q6 h(27例次),各组头孢哌酮血药浓度的中位数分别为34.12 mg·L-1(4.12~177.79 mg·L-1)、31.23 mg·L-1(1.89~251.8 mg·L-1)、59.96 mg·L-1(1.77~140.58 mg·L-1),舒巴坦血药浓度的中位数分别为6.3 mg·L-1(0.61~136.01 mg·L-1)、28.83 mg·L-1(0.5~133.69 mg·L-1)、11.17 mg·L-1(0.73~143.53 mg·L-1)。Mann-Whitney U检验显示,头孢哌酮血药浓度结果无统计学差异(P>0.05),舒巴坦有统计学差异(P<0.05)。结论:本检测方法操作简便、快速、重复性好,可满足临床头孢哌酮与舒巴坦浓度的检测;头孢哌酮/舒巴坦在不同给药方案下血药浓度结果与个体差异相关,有必要开展血药浓度监测并依据结果适时调整用药方案,提高治疗效果减少耐药率的发生。 相似文献
15.
《Journal of pharmaceutical sciences》2019,108(10):3425-3433
This study aimed at evaluating how encapsulation in a regular nanocarrier (NC) (providing extended circulation time) or in a brain-targeting NC (providing prolonged circulation time and increased brain uptake) may influence the therapeutic index compared with the unformulated drug and to explore the key parameters affecting therapeutic performance using a model-based approach. Pharmacokinetic (PK) models were built with chosen PK parameters. For a scenario where central effect depends on area under the unbound brain concentration curve and peripheral toxicity relates to peak unbound plasma concentration, dose-effect and drug-side effect curves were constructed, and the therapeutic index was evaluated. Regular NC improved the therapeutic index compared with the unformulated drug due to reduced peripheral toxicity, while brain-targeting NC enhanced the therapeutic index by lowering peripheral toxicity and increasing central effect. Decreasing drug release rate or systemic clearance of NC with drug still encapsulated could increase the therapeutic index. Also, a drug with shorter half-life would therapeutically benefit more from a NC encapsulation. This work provides insights into how a NC for brain delivery should be optimized to maximize the therapeutic performance and is helpful to predict if and to what extent a drug with certain PK properties would obtain therapeutic benefit from nanoencapsulation. 相似文献
16.
17.
18.
《Journal of pharmaceutical sciences》2019,108(7):2500-2504
Accurately predicting the hepatic clearance of compounds using in vitro to in vivo extrapolation (IVIVE) is crucial within the pharmaceutical industry. However, several groups have recently highlighted the serious error in the process. Although empirical or regression-based scaling factors may be used to mitigate the common underprediction, they provide unsatisfying solutions because the reasoning behind the underlying error has yet to be determined. One previously noted trend was intrinsic clearance-dependent underprediction, highlighting the limitations of current in vitro systems. When applying these generated in vitro intrinsic clearance values during drug development and making first-in-human dose predictions for new chemical entities though, hepatic clearance is the parameter that must be estimated using a model of hepatic disposition, such as the well-stirred model. Here, we examine error across hepatic clearance ranges and find a similar hepatic clearance-dependent trend, with high clearance compounds not predicted to be so, demonstrating another gap in the field. 相似文献
19.
20.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献